Cabaletta Bio (NASDAQ: CABA)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-04 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.600 | -0.450 | 0.1500 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Cabaletta Bio (NASDAQ: CABA) through any online brokerage.
Other companies in Cabaletta Bio’s space includes: Vincerx Pharma (NASDAQ:VINC), Synaptogenix (NASDAQ:SNPX), Brooklyn (NASDAQ:BTX), T2 Biosystems (NASDAQ:TTOO) and Monopar Therapeutics (NASDAQ:MNPR).
The latest price target for Cabaletta Bio (NASDAQ: CABA) was reported by Mizuho on Wednesday, May 25, 2022. The analyst firm set a price target for 10.00 expecting CABA to rise to within 12 months (a possible 890.10% upside). 6 analyst firms have reported ratings in the last year.
The stock price for Cabaletta Bio (NASDAQ: CABA) is $1.01 last updated June 24, 2022, 8:00 PM UTC.
There are no upcoming dividends for Cabaletta Bio.
Cabaletta Bio’s Q2 earnings are confirmed for Thursday, August 4, 2022.
There is no upcoming split for Cabaletta Bio.
Cabaletta Bio is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.